Metraipolis › archive › dc_e927ad2dbcbe

Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event… — Europe PMC PMID:39185318

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/39185318
DOI
10.3389/fphar.2024.1393940
License (as archived)
solo-consultazione
Archived
2026-10-07T14:20:18.235Z
SHA-256 of the archived text
19fec02c1826fe926e20fd736a32dd2a8073668defb2284d7f49d97cebfcf0fe
Stable URL of this page
https://metraipolis.com/documento/dc_e927ad2dbcbe

How to cite

Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event… — Europe PMC PMID:39185318 — Europe PMC (en), https://europepmc.org/article/MED/39185318 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e927ad2dbcbe (Metraipolis archive dc_e927ad2dbcbe, sha256 19fec02c1826fe926e20fd736a32dd2a8073668defb2284d7f49d97cebfcf0fe)
BibTeX
@misc{dce927ad2dbcbe,
  title = {Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event… — Europe PMC PMID:39185318},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/39185318},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e927ad2dbcbe; sha256 19fec02c1826fe926e20fd736a32dd2a8073668defb2284d7f49d97cebfcf0fe},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/39185318. Agents can read the archived copy with the MCP tool read_document.